Changes In Plasma NPY, IL-1β And Hypocretin In People Who Died By Suicide

References

• WHO. Preventing Suicide: A Global Imperative; 2014 Available from: http://www.who.int/mental_health/suicide-prevention/world_report_2014/en/.
   Google Scholar
• Hawton K, van Heeringen K. Suicide. Lancet. 2009;373(9672):1372–1381. doi:10.1016/S0140-6736(09)60372-X19376453
   PubMed Web of Science ®Google Scholar
• Gananca L, Oquendo MA, Tyrka AR, Cisneros-Trujillo S, Mann JJ, Sublette ME. The role of cytokines in the pathophysiology of suicidal behavior. Psychoneuroendocrinology. 2016;63:296–310. doi:10.1016/j.psyneuen.2015.10.00826546783
   PubMed Web of Science ®Google Scholar
• Harro J. CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies. Amino Acids. 2006;31(3):215–230. doi:10.1007/s00726-006-0334-x16738800
   PubMed Web of Science ®Google Scholar
• Serafini G, Pompili M, Lindqvist D, Dwivedi Y, Girardi P. The role of neuropeptides in suicidal behavior: a systematic review. Biomed Res Int. 2013;2013:687575. doi:10.1155/2013/68757523986909
   PubMed Web of Science ®Google Scholar
• Widdowson PS, Ordway GA, Halaris AE. Reduced neuropeptide Y concentrations in suicide brain. J Neurochem. 1992;59(1):73–80. doi:10.1111/j.1471-4159.1992.tb08877.x1613514
   PubMed Web of Science ®Google Scholar
• Heilig M, Zachrisson O, Thorsell A, et al. Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. J Psychiatr Res. 2004;38(2):113–121.14757324
   PubMed Web of Science ®Google Scholar
• Coccaro EF, Lee R, Liu T, Mathe AA. Cerebrospinal fluid neuropeptide Y-like immunoreactivity correlates with impulsive aggression in human subjects. Biol Psychiatry. 2012;72(12):997–1003. doi:10.1016/j.biopsych.2012.07.02922985695
   PubMed Web of Science ®Google Scholar
• van de Veerdonk FL, Netea MG. New insights in the immunobiology of IL-1 family members. Front Immunol. 2013;4:167. doi:10.3389/fimmu.2013.0016723847614
   PubMed Web of Science ®Google Scholar
• Patterson SL. Immune dysregulation and cognitive vulnerability in the aging brain: interactions of microglia, IL-1beta, BDNF and synaptic plasticity. Neuropharmacology. 2015;96(Pt A):11–18. doi:10.1016/j.neuropharm.2014.12.02025549562
   PubMed Web of Science ®Google Scholar
• Monfrim X, Gazal M, De Leon PB, et al. Immune dysfunction in bipolar disorder and suicide risk: is there an association between peripheral corticotropin-releasing hormone and interleukin-1beta? Bipolar Disord. 2014;16(7):741–747. doi:10.1111/bdi.1221424862833
   PubMed Web of Science ®Google Scholar
• Pandey GN, Rizavi HS, Ren X, et al. Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims. J Psychiatr Res. 2012;46(1):57–63. doi:10.1016/j.jpsychires.2011.08.00621906753
   PubMed Web of Science ®Google Scholar
• Grudet C, Malm J, Westrin A, Brundin L. Suicidal patients are deficient in vitamin D, associated with a pro-inflammatory status in the blood. Psychoneuroendocrinology. 2014;50:210–219. doi:10.1016/j.psyneuen.2014.08.01625240206
   PubMed Web of Science ®Google Scholar
• Nollet M, Leman S. Role of orexin in the pathophysiology of depression: potential for pharmacological intervention. CNS Drugs. 2013;27(6):411–422. doi:10.1007/s40263-013-0064-z23657787
   PubMed Web of Science ®Google Scholar
• Brundin L, Petersen A, Bjorkqvist M, Traskman-Bendz L. Orexin and psychiatric symptoms in suicide attempters. J Affect Disord. 2007;100(1–3):259–263. doi:10.1016/j.jad.2006.10.01917141878
   PubMed Web of Science ®Google Scholar
• Brundin L, Bjorkqvist M, Traskman-Bendz L, Petersen A. Increased orexin levels in the cerebrospinal fluid the first year after a suicide attempt. J Affect Disord. 2009;113(1–2):179–182. doi:10.1016/j.jad.2008.04.01118533274
   PubMed Web of Science ®Google Scholar
• Matsuda K, Matsumura K, Shimizu SS, Nakamachi T, Konno N. Neuropeptide Y-induced orexigenic action is attenuated by the orexin receptor antagonist in bullfrog larvae. Front Neurosci. 2017;11:176. doi:10.3389/fnins.2017.0017628420957
   PubMedGoogle Scholar
• Fu LY, Acuna-Goycolea C, van den Pol AN. Neuropeptide Y inhibits hypocretin/orexin neurons by multiple presynaptic and postsynaptic mechanisms: tonic depression of the hypothalamic arousal system. J Neurosci. 2004;24(40):8741–8751. doi:10.1523/JNEUROSCI.2268-04.200415470140
   PubMed Web of Science ®Google Scholar
• Grossberg AJ, Zhu X, Leinninger GM, et al. Inflammation-induced lethargy is mediated by suppression of orexin neuron activity. J Neurosci. 2011;31(31):11376–11386. doi:10.1523/JNEUROSCI.2311-11.201121813697
   PubMed Web of Science ®Google Scholar
• Oquendo MA, Perez-Rodriguez MM, Poh E, et al. Life events: a complex role in the timing of suicidal behavior among depressed patients. Mol Psychiatry. 2014;19(8):902–909. doi:10.1038/mp.2013.12824126928
   PubMed Web of Science ®Google Scholar
• Brundin L, Bjorkqvist M, Petersen A, Traskman-Bendz L. Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. Eur Neuropsychopharmacol. 2007;17(9):573–579. doi:10.1016/j.euroneuro.2007.01.00517346943
   PubMed Web of Science ®Google Scholar
• Traskman L, Asberg M, Bertilsson L, Sjostrand L. Monoamine metabolites in CSF and suicidal behavior. Arch Gen Psychiatry. 1981;38(6):631–636. doi:10.1001/archpsyc.1981.017803100310026166274
   PubMed Web of Science ®Google Scholar
• Schmeltzer SN, Herman JP, Sah R. Neuropeptide Y (NPY) and posttraumatic stress disorder (PTSD): a translational update. Exp Neurol. 2016;284(Pt B):196–210. doi:10.1016/j.expneurol.2016.06.02027377319
   PubMed Web of Science ®Google Scholar
• Ozsoy S, Olguner Eker O, Abdulrezzak U. The effects of antidepressants on neuropeptide Y in patients with depression and anxiety. Pharmacopsychiatry. 2016;49(1):26–31. doi:10.1055/s-0035-156524126789271
   PubMed Web of Science ®Google Scholar
• Irwin M, Brown M, Patterson T, Hauger R, Mascovich A, Grant I. Neuropeptide Y and natural killer cell activity: findings in depression and alzheimer caregiver stress. Faseb J. 1991;5(15):3100–3107. doi:10.1096/fasebj.5.15.17434411743441
   PubMed Web of Science ®Google Scholar
• Roy A. Neuropeptides in relation to suicidal behavior in depression. Neuropsychobiology. 1993;28(4):184–186. doi:10.1159/0001190217903797
   PubMed Web of Science ®Google Scholar
• Peters J, Van Kammen DP, Gelernter J, Yao J, Shaw D. Neuropeptide Y-like immunoreactivity in schizophrenia. Relationships with clinical measures. Schizophr Res. 1990;3(5–6):287–294. doi:10.1016/0920-9964(90)90012-v2178001
   PubMed Web of Science ®Google Scholar
• Nolan KA, D’Angelo D, Hoptman MJ. Self-report and laboratory measures of impulsivity in patients with schizophrenia or schizoaffective disorder and healthy controls. Psychiatry Res. 2011;187(1–2):301–303. doi:10.1016/j.psychres.2010.10.03221106252
   PubMed Web of Science ®Google Scholar
• Harrison A, Genders R, Davies H, Treasure J, Tchanturia K. Experimental measurement of the regulation of anger and aggression in women with anorexia nervosa. Clin Psychol Psychother. 2011;18(6):445–452. doi:10.1002/cpp.72620859934
   PubMed Web of Science ®Google Scholar
• Liu ZZ, Chen H, Bo QG, et al. Psychological and behavioral characteristics of suicide attempts and non-suicidal self-injury in Chinese adolescents. J Affect Disord. 2018;226:287–293. doi:10.1016/j.jad.2017.10.01029024902
   PubMed Web of Science ®Google Scholar
• Alasaarela L, Hakko H, Riala K, Riipinen P. Association of self-reported impulsivity to nonsuicidal self-injury, suicidality, and mortality in adolescent psychiatric inpatients. J Nerv Ment Dis. 2017;205(5):340–345. doi:10.1097/NMD.000000000000065528141633
   PubMed Web of Science ®Google Scholar
• Zukowska-Grojec Z, Wahlestedt C. Origin and actions of neuropeptide Y in the cardiovascular system In: Colmers WF, Wahlestedt C, editors. The Biology of Neuropeptide Y and Related Peptides. Totowa, NJ: Humana Press; 1993:315–388.
   Google Scholar
• Oztas B, Sahin D, Kir H, et al. The effect of leptin, ghrelin, and neuropeptide-Y on serum Tnf-alpha, Il-1beta, Il-6, Fgf-2, galanin levels and oxidative stress in an experimental generalized convulsive seizure model. Neuropeptides. 2017;61:31–37. doi:10.1016/j.npep.2016.08.00227522536
   PubMed Web of Science ®Google Scholar
• Ferreira R, Santos T, Viegas M, et al. Neuropeptide Y inhibits interleukin-1beta-induced phagocytosis by microglial cells. J Neuroinflammation. 2011;8:169. doi:10.1186/1742-2094-8-7222136135
   PubMed Web of Science ®Google Scholar
• Pandey GN. Inflammatory and innate immune markers of neuroprogression in depressed and teenage suicide brain. Mod Trends Pharmacopsychiatry. 2017;31:79–95. doi:10.1159/00047080928738369
   PubMedGoogle Scholar
• Gabbay V, Klein RG, Guttman LE, et al. A preliminary study of cytokines in suicidal and nonsuicidal adolescents with major depression. J Child Adolesc Psychopharmacol. 2009;19(4):423–430. doi:10.1089/cap.2008.014019702494
   PubMed Web of Science ®Google Scholar
• Melhem NM, Munroe S, Marsland A, et al. Blunted HPA axis activity prior to suicide attempt and increased inflammation in attempters. Psychoneuroendocrinology. 2017;77:284–294. doi:10.1016/j.psyneuen.2017.01.00128135675
   PubMed Web of Science ®Google Scholar
• Tonelli LH, Stiller J, Rujescu D, et al. Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. Acta Psychiatr Scand. 2008;117(3):198–206. doi:10.1111/j.1600-0447.2007.01128.x18081924
   PubMed Web of Science ®Google Scholar
• Lu J, Zhao J, Balesar R, et al. Sexually dimorphic changes of hypocretin (orexin) in depression. EBioMedicine. 2017;18:311–319. doi:10.1016/j.ebiom.2017.03.04328377228
   PubMed Web of Science ®Google Scholar
• Chien YL, Liu CM, Shan JC, et al. Elevated plasma orexin A levels in a subgroup of patients with schizophrenia associated with fewer negative and disorganized symptoms. Psychoneuroendocrinology. 2015;53:1–9. doi:10.1016/j.psyneuen.2014.12.01225560205
   PubMed Web of Science ®Google Scholar
• Schmidt FM, Arendt E, Steinmetzer A, et al. CSF-hypocretin-1 levels in patients with major depressive disorder compared to healthy controls. Psychiatry Res. 2011;190(2–3):240–243. doi:10.1016/j.psychres.2011.06.00421757240
   PubMed Web of Science ®Google Scholar
• Akimoto-Takano S, Sakurai C, Kanai S, Hosoya H, Ohta M, Miyasaka K. Differences in the appetite-stimulating effect of orexin, neuropeptide Y and ghrelin among young, adult and old rats. Neuroendocrinology. 2005;82(5–6):256–263. doi:10.1159/00009275416721031
   PubMed Web of Science ®Google Scholar
• Volkoff H, Peter RE. Interactions between orexin A, NPY and galanin in the control of food intake of the goldfish, carassius auratus. Regul Pept. 2001;101(1–3):59–72. doi:10.1016/s0167-0115(01)00261-011495680
   PubMedGoogle Scholar
• Russell SH, Small CJ, Dakin CL, et al. The central effects of orexin-A in the hypothalamic-pituitary-adrenal axis in vivo and in vitro in male rats. J Neuroendocrinol. 2001;13(6):561–566.11412343
   PubMed Web of Science ®Google Scholar
• Jaszberenyi M, Bujdoso E, Kiss E, Pataki I, Telegdy G. The role of NPY in the mediation of orexin-induced hypothermia. Regul Pept. 2002;104(1–3):55–59. doi:10.1016/s0167-0115(01)00339-111830277
   PubMedGoogle Scholar
• Baranowska B, Wolinska-Witort E, Martynska L, Chmielowska M, Baranowska-Bik A. Plasma orexin A, orexin B, leptin, neuropeptide Y (NPY) and insulin in obese women. Neuro Endocrinol Lett. 2005;26(4):293–296.16135994
   PubMed Web of Science ®Google Scholar
• Raposo NR, Ferreira AS, Gattaz WF. Body mass index increase, serum leptin, adiponectin, neuropeptide Y and lipid levels during treatment with olanzapine and haloperidol. Pharmacopsychiatry. 2011;44(5):169–172. doi:10.1055/s-0031-128079321732272
   PubMed Web of Science ®Google Scholar
• Fornaro M, Rocchi G, Escelsior A, Contini P, Martino M. Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds. J Affect Disord. 2013;145(3):300–307. doi:10.1016/j.jad.2012.08.00722981313
   PubMed Web of Science ®Google Scholar
• Chen CY, Yeh YW, Kuo SC, et al. Differences in immunomodulatory properties between venlafaxine and paroxetine in patients with major depressive disorder. Psychoneuroendocrinology. 2018;87:108–118. doi:10.1016/j.psyneuen.2017.10.00929055264
   PubMed Web of Science ®Google Scholar
• Bleeker MW, Netea MG, Kullberg BJ, Van der Ven-Jongekrijg J, Van der Meer JW. The effects of dexamethasone and chlorpromazine on tumour necrosis factor-alpha, interleukin-1 beta, interleukin-1 receptor antagonist and interleukin-10 in human volunteers. Immunology. 1997;91(4):548–552. doi:10.1046/j.1365-2567.1997.00285.x9378493
   PubMed Web of Science ®Google Scholar
• Obuchowicz E, Turchan J. Effects of acute or long-term treatment with chlorpromazine, haloperidol or sulpiride on neuropeptide Y-like immunoreactivity concentrations in the nucleus accumbens of rat. Eur Neuropsychopharmacol. 1999;9(1–2):51–59.10082228
   PubMed Web of Science ®Google Scholar